



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>7</sup> : C12N 15/31, 15/62, 1/21, C07K 14/33, A61K 38/16</p>	A1	<p>(11) International Publication Number: <b>WO 00/61762</b></p> <p>(43) International Publication Date: 19 October 2000 (19.10.00)</p>									
<p>(21) International Application Number: PCT/US00/09525</p> <p>(22) International Filing Date: 10 April 2000 (10.04.00)</p> <p>(30) Priority Data:</p> <table border="0"> <tr> <td>60/128,686</td> <td>9 April 1999 (09.04.99)</td> <td>US</td> </tr> <tr> <td>60/186,201</td> <td>1 March 2000 (01.03.00)</td> <td>US</td> </tr> <tr> <td>60/190,111</td> <td>20 March 2000 (20.03.00)</td> <td>US</td> </tr> </table> <p>(71) Applicant: TECHLABS, INC. [US/US]; 1861 Pratt Drive, Blacksburg, VA 24060-6364 (US).</p> <p>(72) Inventors: WILKINS, Tracy, D.; 6254 Chestnut Ridge Road, Riner, VA 24149 (US). LYLERLY, David, M.; 204 MacArthur Avenue, Radford, VA 24141 (US). MONCRIEF, J., Scott; 615 Charles Street, Christiansburg, VA 24073 (US). ZHENG, Limin; Techlabs, Inc., 1861 Pratt Drive, Blacksburg, VA 24060-6364 (US). PHELPS, Carol; Floyd, VA (US).</p> <p>(74) Agents: MAYS, Thomas, D. et al.; Morrison &amp; Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).</p>		60/128,686	9 April 1999 (09.04.99)	US	60/186,201	1 March 2000 (01.03.00)	US	60/190,111	20 March 2000 (20.03.00)	US	<p>(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
60/128,686	9 April 1999 (09.04.99)	US									
60/186,201	1 March 2000 (01.03.00)	US									
60/190,111	20 March 2000 (20.03.00)	US									
<p>(54) Title: RECOMBINANT TOXIN A/TOXIN B VACCINE AGAINST <i>CLOSTRIDIUM DIFFICILE</i></p>											
<p>Glucosyltransferase Domain</p> <p>Binding Domain</p> <p>Active site DXD motif</p> <p>Repeating units</p>											
<p>(57) Abstract</p> <p>The present invention relates to the field of medical immunology and further to pharmaceutical compositions, methods of making and methods of use of vaccines. More specifically this invention relates to recombinant proteins derived from the genes encoding <i>Clostridium difficile</i> toxin A and toxin B, and their use in an active vaccine against <i>C. difficile</i>.</p>											

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

RECOMBINANT TOXIN A/TOXIN B VACCINE  
AGAINST *CLOSTRIDIUM DIFFICILE*

TECHNICAL FIELD OF INVENTION

The present invention relates to the field of medical immunology and further to pharmaceutical compositions, methods of making and methods of use of vaccines. More specifically this invention relates to recombinant proteins derived from the genes encoding *Clostridium difficile* toxin A and toxin B, and their use in an active vaccine against *C. difficile*.

BACKGROUND OF THE INVENTION

*Clostridium difficile*, a Gram positive anaerobic spore-forming bacillus is an etiologic agent of antibiotic associated diarrhea (AAD) and colitis (AAC). The symptoms of the disease range from mild diarrhea to fulminant and life-threatening pseudomembranous colitis (PMC). Antibiotic therapy can disrupt the normal intestinal microflora. Destruction of the normal flora results in a condition in which *C. difficile* can spores of *C. difficile* can germinate and the organism can grow and produce disease causing toxins. *C. difficile* causes about 25% of antibiotic-associated diarrheas, however, it is almost always the causative agent of PMC (Lyerly, D.M. and T.D. Wilkins, in *Infections of the Gastrointestinal Tract*, Chapter 58, pages 867-891, (Raven Press, Ltd, New York 1995)). Additionally, *C. difficile* is frequently identified as a causative agent of nosocomial infectious diarrheas, particularly in older or immuno-compromised patients (U.S. Pat. No. 4,863.852 (Wilkins *et al.*) (1989)).

Disease caused by *C. difficile* is due to two enteric toxins A and B produced by toxigenic strains (U.S. Pat. No. 5,098,826 (Wilkins *et al.*) (1992)). Toxin A is an enterotoxin with minimal cytotoxic activity, whereas toxin B is a potent cytotoxin but has limited enterotoxic activity. The extensive damage to the intestinal mucosa is attributable to the action of toxin A, however, toxins A and B act synergistically in the intestine.

The genetic sequences encoding both toxigenic proteins A and B, the largest known bacterial toxins, with molecular weights of 308,000 and 269,000, respectively, have been elucidated (Moncrief *et al.*, *Infect. Immun.* 65:1105-1108 (1997); Barroso *et al.*, *Nucl. Acids Res.* 18:4004 (1990); Dove *et al.* *Infect. Immun.* 58:480-488 (1990)). Because of the degree of similarity when conserved substitutions are considered, these toxins are thought to have arisen from gene duplication. The proteins share a number of similar structural features with one another. For example, both proteins possess a putative nucleotide

binding site, a central hydrophobic region, four conserved cysteines and a long series of repeating units at their carboxyl ends. The repeating units of toxin A, particularly, are immunodominant and are responsible for binding to type 2 core carbohydrate antigens on the surface of the intestinal epithelium (Krivan *et al.*, *Infect. Immun.* 53:573-581 (1986); Tucker, K. and T.D. Wilkins, *Infect. Immun.* 59:73-78 (1991)).

The toxins share a similar molecular mechanism of action involving the covalent modification of Rho proteins. Rho proteins are small molecular weight effector proteins that have a number of cellular functions including maintaining the organization of the cytoskeleton. The covalent modification of Rho proteins is due to glucosyltransferase activity of the toxins. A glucose moiety is added to Rho using UDP-glucose as a co-substrate (Just *et al.* *Nature* 375:500-503 (1995), Just *et al.* *J. Biol. Chem* 270:13932-13939 (1995)). The glucosyltransferase activity has been localized to approximately the initial 25% of the amino acid sequence of each of these toxins (Hofmann *et al.* *J. Biol. Chem.* 272:11074-11078 (1997), Faust and Song, *Biochem. Biophys. Res. Commun.* 251:100-105 (1998)) leaving a large portion of the toxins, including the repeating units, that do not participate in the enzymatic activity responsible for cytotoxicity.

The toxin A protein comprises 31 contiguous repeating units ( *rARU* ) and may contain multiple T cell epitopes (Dove *et al.* *Infect. Immun.* 58:480-488 (1990)). The repeating units are defined as class I repeats and class II. *rARU* may be uniquely suited for use in inducing T cell-dependent response to an antigen. The sequence of each unit is similar but not identical. These features along with its usefulness in eliciting toxin A neutralizing antibodies make *rARU* a novel candidate as a carrier protein.

The toxin B repeating units have similar features to those of *rARU*. Like *rARU*, the recombinant toxin B repeating units (*rBRU*) are relatively large (~70 kDa) and are composed of contiguous repeats of similar amino acid sequences (Barroso *et al.* *Nucleic Acids Res.* 18:4004 (1990); Eichel-Streiber *et al.* *Gene* 96:107-113 (1992)). Less is known about this portion of toxin B than the binding domain of toxin A.

Thomas *et al.* (U.S. Pat. No. 5,919,463 (1999)) disclose *C. difficile* toxin A or toxin B or certain fragments thereof as mucosal adjuvants intranasally administered to stimulate an immune response to an antigen (e.g., *Helicobacter pylori* urease, ovalbumin (OVA), or keyhole limpet hemocyanin (KLH)). However, Thomas does not teach the use of such adjuvant for protection against strains of *C. difficile*. Lysterly *et al.* *Current Microbiology* 21:29-32 (1990) considered a smaller recombinant fragment from the toxin A repeats in

hamster protection assays. However, these data suggest at best only a very weak or partial protection from strains of *C. difficile*, whereas the present invention demonstrates the use of *C. difficile* toxin repeating units that provide a clear immunogenic response and at higher levels, which afford protection against *C. difficile*.

Even were one to consider *rARU* and *rBRU* as candidate proteins for conjugate vaccines, the production of such proteins presents certain challenges. There are methods for the production of toxin A and antibodies elicited thereto (U.S. Pat. No. 4,530,833 (Wilkins *et al.*)(1985); U.S. Pat. No. 4,533,630 (Wilkins *et al.*)(1985); and U.S. Pat. No. 4,879,218 (Wilkins *et al.*)(1989)). There are significant difficulties in producing sufficient quantities of the *C. difficile* toxin A and toxin B proteins. These methods are generally cumbersome and expensive. However, the present invention provides for the construction and recombinant expression of a nontoxic truncated portions or fragments of *C. difficile* toxin A and toxin B in strains of *E. coli*. Such methods are more effective and commercially feasible for the production of sufficient quantities of a protein molecule for raising humoral immunogenicity to antigens.

Part of the difficulty that the present invention overcomes concerns the fact that large proteins are difficult to express at high levels in *E. coli*. Further, an unusually high content of AT in these clostridial gene sequences (i.e., AT-rich) makes them particularly difficult to express at high levels (Makoff *et al. Bio/Technology* 7:1043-1046 (1989)). It has been reported that expression difficulties are often encountered when large (i.e., greater than 100 kd) fragments are expressed in *E. coli*. A number of expression constructs containing smaller fragments of the toxin A gene have been constructed, to determine if small regions of the gene can be expressed to high levels without extensive protein degradation. In all cases, it was reported that higher levels of intact, full length fusion proteins were observed rather than the larger recombinant fragments (Kink *et al.*, U.S. Pat. No. 5,736,139; see: Example 11(c)). It has been further reported that AT-rich genes contain rare codons that are thought to interfere with their high-level expression in *E. coli* (Makoff *et al. Nucleic Acids Research* 17:10191-10202). The present invention provides for methods to produce genes that are both large and AT-rich and immunogenic compositions thereof. For example, the toxin A repeating units are approximately 98 kDa and the gene sequence has an AT content of approximately 70% that is far above the approximately 50% AT content of the *E. coli* genome. The present invention provides for

methods of expressing AT-rich genes (including very large ones) at high levels in *E. coli* without changing the rare codons or supplying rare tRNA.

Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents. Further, all documents referred to throughout this application are incorporated in their entirety by reference herein. Specifically, the present application claims benefit of priority to U.S. provisional patent application serial number 60/190,111, which was filed on March 20, 2000; and U.S. provisional patent application serial number 60/186,201, which was filed on March 1, 2000; and U.S. provisional patent application serial number 60/128,686, which was filed on April 9, 1999, and which provisional patent applications are incorporated in their entirety by reference herein.

#### SUMMARY OF THE INVENTION

The present invention is drawn to an immunogenic composition that includes recombinant proteins. The genes encoding the proteins are isolated from a strain of *C. difficile*. A preferred embodiment of this invention provides that at least one protein is a toxin or a toxin fragment. A further preferred embodiment provides that the toxin is *C. difficile* toxin A or toxin B. A more preferred embodiment of the present invention provides that the recombinant protein components are nontoxic and comprise a portion of both toxins including all of the amino acid sequence of the *C. difficile* toxin A or toxin B repeating units (*r*ARU or *r*BRU) or fragment thereof. The immunogenic composition may further include a carbohydrate moiety as well as a pharmaceutically acceptable carrier or other compositions in a formulation suitable for injection in a mammal.

Another embodiment of the invention is that the *r*ARU and *r*BRU components are combined, preferably in a manner that results in high levels of neutralizing antibodies to toxins A and B when the immunogenic composition is used in vaccine. The components may be admixed at different ratios. Further, the *r*ARU and *r*BRU components may be chemically or physically linked to form a complex. Another preferred embodiment is that the *r*ARU and *r*BRU sequences, or fragments thereof, may be genetically fused in a manner that results in the production of a hybrid molecule. A further embodiment is that the immunogenic composition elicits antibodies that precipitate the native *C. difficile* toxins

and neutralize their cytotoxic activity thus providing protection against *C. difficile* associated disease.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1. Schematic of toxins A and B. The repeating units of the toxins function in binding to the cell surface. Antibodies to the repeating units of the toxins neutralize cytotoxic activity by blocking the binding of the toxins to the cell surface.

Fig. 2 shows the nucleotide sequence (numbers 5690-8293, GenBank accession number M30307, Dove *et al.* 1993) of the toxin A gene region that encodes *r*ARU and the toxin A stop codon. The sequence encodes for the entire repeating units of toxin A from *C. difficile* strain VPI 10463 as defined by Dove *et al.* (Dove *et al.*, *Infect Immun.* 58:480-488 (1990)). In addition it encodes for 4 amino acids upstream of the beginning of the repeating units and a small stretch of hydrophobic amino acids at the end of toxin A. The *Sau*3A site (underlined) at the beginning of the sequence was used to subclone the gene fragment to an expression vector. The stop codon at the end of the sequence is italicized.

Fig. 3 shows the amino acid sequence (GenBank accession number M303307) of *r*ARU. The invention contemplates the use of any recombinant protein containing this amino acid sequence, any fragment therein, any fusion protein containing *r*ARU or a fragment therein, and any larger fragment from toxin A carrying all or part of *r*ARU, as a carrier for conjugate vaccine compositions.

Fig. 4 shows the expression vector pRSETB-ARU-Km<sup>r</sup> used for expression of *r*ARU. A *Sau*3A/*Hind*III gene fragment of approximately 2.7 kb containing the entire nucleotide sequence encoding *r*ARU, stop codon, and a small region downstream of the toxin A stop codon, was subcloned to the vector pRSETB digested with *Bam*HI and *Hind*III. In a subsequent step the kanamycin resistance gene was subcloned at the *Hind*III site located downstream of the *r*ARU gene fragment. The 1.2 kb fragment encoding the Km<sup>r</sup> gene was derived from pUC4K (GenBank accession number X06404) by digestion with *Eco*RI and subcloned at the *Hind*III site after blunt ending of the vector and Km<sup>r</sup> cassette with Klenow fragment. Expression vector pRSETB-ARU-Km<sup>r</sup> was transformed into BL21(DE3) for expression of *r*ARU under control of the T7 promoter.

\* *Hind*III/*Eco*RI sites were eliminated by blunt ending.

Fig. 5 shows an SDS-PAGE gel (15% acrylamide) of *r*ARU expression and purification steps. Lanes: 1) 4  $\mu$ l of 10X BL21(DE3) *E. coli*/pRSETB-ARU-Km<sup>r</sup> lysate 2) 4  $\mu$ l of dialyzed 40% ammonium sulfate fraction at 10X relative to the original culture

volume 3) 5  $\mu$ l *r*ARU (0.88 mg/ml) purified by CL-6B Sepharose anion exchange chromatography.

Fig. 6 shows the nucleotide sequence (GenBank accession number X531138, Wilkins *et al.* 1990) of the toxin B gene region that encodes *r*BRU and a small portion upstream. The *Sau*3a restriction sites used for subcloning are underlined. The sequence of the repeating units of toxin B from *C. difficile* strain VPI was defined previously (Eichel-Streiber *et al. Mol. Gen. Gen.* 233:260-268).

Fig. 7 shows the amino acid sequence (GenBank accession number X53138) of *r*BRU and a small upstream region. The invention contemplates the use of any recombinant protein containing this amino acid sequence, any fragment therein, any fusion protein containing *r*BRU or a fragment therein, and any larger fragment from toxin B carrying all or part of *r*BRU, as a component in a vaccine against *C. difficile*.

Fig. 8 shows the expression vector pRSETC-BRU-Km<sup>r</sup> used for expression of *r*BRU. A gene fragment of approximately 1.8 kb containing nearly the entire nucleotide sequence encoding *r*BRU (final 10 amino acids of toxin B are eliminated) was subcloned from the toxin B gene (Phelps *et al. Infect. Immun.* 59:150-153 (1991)) to pGEX-3X. A *Bam*HI/*Eco*RI from pGEX-3X-BRU was subcloned to pRSETC. In a subsequent step the kanamycin resistance gene was subcloned at the *Eco*RI site located downstream of the *r*BRU gene fragment. The 1.2 kb fragment encoding the Km<sup>r</sup> gene was derived from pUC4K (GenBank accession number X06404) by digestion with *Eco*RI. Expression vector pRSETC-BRU-Km<sup>r</sup> was transformed into BL21(DE3) for expression of *r*BRU under control of the T7 promoter.

Fig. 9. SDS-PAGE of purified *r*ARU and partially purified *r*BRU. Lanes; 1) *r*ARU purified by sequential ammonium sulfate precipitation and Sepharose CL-6B anion exchange chromatography, 2) *r*BRU partially purified by ammonium sulfate precipitation and hydrophobic interaction chromatography on phenyl Sepharose, 3) lysate (10X concentration) of *Escherichia coli* BL21(DE3)/pRSETC-BRU-Km<sup>r</sup>.

Fig. 10. Crossed-immunoelectrophoresis of (A) *C. difficile* culture filtrate and (B) partially purified *r*BRU. *C. difficile* goat antisera was used as the precipitating antibody.

Fig. 11. shows an example of a genetic fusion of *r*ARU and *r*BRU. A *Sau*3A/*Eco*RI toxin A gene fragment (nucleotides 5530 through 6577) may be fused to an *Apo*I toxin B gene fragment (nucleotides 5464 through 6180) to create an in-frame 1,763 bp gene fusion expressing a 588 amino acid *r*ARU'*r*BRU' fusion protein of approximately 68 kDa

containing a significant portion of the repeating units from both toxin genes. The *rARU*' fragment encodes an epitope for PCG-4 represented by the open bar in the *rARU*' portion of the gene fusion.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention is drawn to an immunogenic composition that includes at least one recombinant protein component, wherein the gene encoding the protein component is isolated from a strain of *Clostridium difficile*. A preferred embodiment of this invention provides that the protein is a toxin or a toxin fragment. An even further preferred embodiment provides that the toxin is toxin A, with yet a further preferred embodiment being a portion of the toxin containing all of the amino acid sequence of the toxin A repeating units (*rARU*) or fragment thereof. Another preferred embodiment is that the toxin is toxin B, with yet another preferred embodiment being a portion of the toxin containing all of the amino acid sequence of the repeating units (*rBRU*) or a fragment thereof. The immunogenic composition may further include a pharmaceutically acceptable carrier or other compositions in a formulation suitable for injection in a mammal.

These immunogenic compositions of the present invention elicit an immune response in a mammalian host, including humans and other animals. The immune response may be either a cellular dependent response or an antibody dependent response or both and further the response may provide immunological memory or a booster effect or both in the mammalian host. These immunogenic compositions are useful as vaccines and may provide a protective response by the mammalian subject or host to infection by strains of *Clostridium difficile*.

The present invention further includes methods for producing an immunogenic composition by: constructing a genetic sequence encoding a recombinant protein component, where the gene encoding the protein component is isolated from a strain of *Clostridium difficile*, expressing the recombinant protein component in a microbial host; recovering the recombinant protein from a culture of the host; conjugating the protein to a second protein component, and recovering the conjugated protein and polysaccharide component. The protein component may also consist of a fusion protein, whereby a portion of said recombinant protein is genetically fused to a second protein component. Preferably the expression of the genetic sequence is regulated by an inducible promoter that is operatively positioned upstream of the sequence and is functional in the host. Even further,

said genetic sequence is maintained throughout the growth of the host by constant and stable selective pressure. Maintenance of the expression vector may be conferred by incorporation in the expression vector of a genetic sequence that encodes a selective genotype, the expression of which in the microbial host cell results in a selective phenotype. Such selective genotypes, include a gene encoding resistance to antibiotics, such as kanamycin. The expression of this selective genotypic sequence on the expression vector in the presence of a selective agent or condition, such as the presence of kanamycin, results in stable maintenance of the vector throughout growth of the host. A selective genotype sequence could also include a gene complementing a conditional lethal mutation.

Other genetic sequences may be incorporated in the expression vector, such as other drug resistance genes or genes that complement lethal mutations.

Microbial hosts of this invention may include: Gram positive bacteria; Gram negative bacteria, preferably *E. coli*; yeasts; filamentous fungi; mammalian cells; insect cells; or plant cells.

The methods of the present invention also provide for a level of expression of the recombinant protein in the host at a level greater than about 10 mg/liter of the culture, more preferably greater than about 50 mg/liter and even more preferably at 100 mg/liter or greater than about 100 mg/liter. The molecular weight of the protein is greater than about 30 kDa, preferably greater than about 50 kDa and even more preferably greater than about 90 kDa. This invention also provides that the protein may be recovered by any number of methods known to those in the art for the isolation and recovery of proteins, but preferably the recovery is by ammonium sulfate precipitation followed by ion exchange chromatography.

The present invention further includes methods for preparing the immunogenic composition that provides that the protein component is conjugated to a second protein component by one of a number of means known to those in the art, particularly an amidization reaction.

Also, high yields of recombinant protein may be dependent on the growth conditions, the rate of expression, and the length of time used to express AT-rich gene sequences. In general, AT-rich genes appear to be expressed at a higher level in *E. coli* during a post-exponential or slowed phase of growth. High-level production of the encoded protein requires moderate levels of expression over an extended period (e.g. 20-24 h) of post-exponential growth rather than the typical approach of high-level expression

during exponential growth for shorter periods (e.g. 4-6 h). In this regard, it is more efficient to maintain plasmids carrying the gene of interest by maintaining constant selective pressure for the gene or its expression vector during the extended period of growth. One aspect of the present invention is using an antibiotic that is not inactivated or degraded during growth of the expression host cell as is found with ampicillin. One such preferred embodiment involves the expression of genes encoding resistance to kanamycin as the selective phenotype for maintaining the expression vector which comprises such kanamycin resistance genetic sequences. Expression of large AT-rich clostridial genes in *E. coli* at levels (> 100 mg/liter) provided for by methods of the present invention was hitherto unknown.

Terms as used herein are based upon their art recognized meaning and should be clearly understood by the ordinary skilled artisan.

An immunogenic composition is any composition of material that elicits an immune response in a mammalian host when the immunogenic composition is injected or otherwise introduced. The immune response may be humoral, cellular, or both.

A fusion protein is a recombinant protein encoded by a gene or fragment of a gene, genetically fused to another gene or fragment of a gene.

A booster effect refers to an increased immune response to an immunogenic composition upon subsequent exposure of the mammalian host to the same immunogenic composition. A humoral response results in the production of antibodies by the mammalian host upon exposure to the immunogenic composition.

*r*ARU is a recombinant protein containing the repeating units of *Clostridium difficile* toxin A as defined by Dove *et al.* (Dove *et al. Infect. Immun.* 58:480-488 (1990)). The nucleotide sequence encoding *r*ARU and the amino acid sequence of *r*ARU are shown in Figs. 2 and 3, respectively. The *r*ARU expressed by pRSETB-ARU-Km<sup>r</sup> contains the entire repeating units region of toxin A. The invention further contemplates the use of this recombinant protein component, or any other protein component containing the entire repeating units of toxin A or any fragment therein, whether expressed alone or as a fusion protein.

Similar methods may be used to isolate, clone and express a recombinant protein component comprising the repeating units of *Clostridium difficile* toxin B (*r*BRU). The nucleotide sequence encoding *r*BRU and the amino acid sequence of *r*BRU are shown in

Figs. 6 and 7, respectively. The *r*BRU expressed by pRSETC-BRU-Km<sup>r</sup> contains the entire repeating units region of toxin B (see Fig. 8).

The present methods provide for preparation of immunogenic compositions comprising *r*ARU or *r*BRU or both, which are useful as vaccines. Immunogenic compositions may be formulated as vaccines in a pharmaceutically acceptable carrier or diluent (e.g., water, a saline solution (e.g., phosphate-buffered saline), a bicarbonate solution (e.g., 0.24 M NaHCO<sub>3</sub>), a suppository, cream, or jelly), which are selected on the basis of the mode and route of administration, and standard pharmaceutical practice, see: U.S. Patent 5,919,463 Thomas, et al., (1999), which is incorporated in its entirety by reference herein. Suitable pharmaceutical carriers and diluents, as well as pharmaceutical necessities for their use in pharmaceutical formulations, are described in Remington's Pharmaceutical Sciences (Alfonso Gennaro et al., eds., 17th edn., Mack Publishing Co., Easton Pa., 1985), a standard reference text in this field, in the USP/NF, and by Lachman et al. (The Theory & Practice of Industrial Pharmacy, 2nd edn., Lea & Febiger, Philadelphia Pa., 1976). In the case of rectal and vaginal administration, the vaccines are administered using methods and carriers standardly used in administering pharmaceutical materials to these regions. For example, suppositories, creams (e.g., cocoa butter), or jellies, as well as standard vaginal applicators, droppers, syringes, or enemas may be used, as determined to be appropriate by one skilled in the art.

The vaccine compositions of the invention may be administered by any route clinically indicated, such as by application to the surface of mucosal membranes (including: intranasal, oral, ocular, gastrointestinal, rectal, vaginal, or genito-urinary). Alternatively, parenteral (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular) modes of administration may also be used. The amounts of vaccine administered depend on the particular vaccine antigen and any adjuvant employed; the mode and frequency of administration; and the desired effect (e.g., protection and/or treatment), as determined by one skilled in the art. In general, the vaccines of the invention will be administered in amounts ranging between 1 µg and 100 mg. Administration is repeated as is determined to be necessary by one skilled in the art. For example, a priming dose may be followed by 3 booster doses at weekly intervals.

Having now generally described the invention, the same will be more readily understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

## EXAMPLES

## EXAMPLE 1

Construction of *r*ARU expression vector.

The vector pRSETB-ARU-Km<sup>r</sup> used for expression and purification was constructed using standard techniques for cloning (Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (1989)). The nucleotide sequence of the toxin A gene fragment encoding *r*ARU was derived from the cloned toxin A gene (Dove *et al.*, *Infect. Immun.* 58:480-488 (1990); Phelps *et al.*, *Infect Immun.* 59:150-153 (1991)) and is shown in Fig. 2. The gene fragment encodes a protein 867 amino acids in length (Fig. 3) with a calculated molecular weight of 98 kDa. The gene fragment was subcloned to the expression vector pRSETB. A kanamycin resistance gene was subsequently subcloned to the vector. The resulting vector pRSETB-ARU-Km<sup>r</sup> expresses *r*ARU. An additional 31 amino acids at the N-terminus of the recombinant protein are contributed by the expression vector pRSETB. The final calculated molecular weight of the recombinant protein is 102 kDa.

## EXAMPLE 2

Expression and purification of *r*ARU.

*Escherichia coli* T7 expression host strain BL21(DE3) was transformed with pRSETB-ARU-Km<sup>r</sup> as described (Sambrook *et al.* *Molecular Cloning: A Laboratory Manual* (1989)). One liter cultures were inoculated with 10 ml of overnight growth of *Escherichia coli* BL21(DE3) containing pRSETB-ARU-Km<sup>r</sup> and grown at 37°C in Terrific broth (Sigma, St. Louis, MO) containing 25 µg/ml of kanamycin to an O.D. 600 of 1.8-2.0 and isopropyl B-D-thiogalactopyranoside (IPTG) was added to a final concentration of 40 µM. Cells were harvested after 22 h of induction, suspended in 0.1 liter of standard phosphate buffered saline, pH 7.4, containing 0.2 % casamino acids, and disrupted by sonication. Cellular debris was removed from the lysate by centrifugation. Lysates typically contained a titer (reciprocal of the highest dilution with an  $A_{450}$  greater than 0.2) of 10<sup>6</sup> in the TOX-A test EIA (TechLab, Inc., Blacksburg, VA). Lysates were saturated with 40% ammonium sulfate, stirred at 4°C overnight and precipitating proteins were harvested by centrifugation. The ammonium sulfate fraction was suspended in 0.1 liters of 5 mM K<sub>2</sub>PO<sub>4</sub>, 0.1 M NaCl<sub>2</sub>, pH 8.0 and dialyzed extensively against the same buffer at 4°C. Insoluble material was removed by centrifugation. The dialyzed solution was passed

through a column containing Sepharose CL-6B chromatography media (50 ml media/100 ml solution). Fractions were collected and monitored for the presence of *r*ARU by EIA using the TOX-A test. Fractions containing EIA activity were analyzed by SDS-PAGE for the presence of *r*ARU at a molecular weight of approximately 102 kDa. Fractions containing a single band of *r*ARU were pooled. To further ensure purity the pooled solution was again passed over a Sepharose CL-6B column (25 ml media/100 ml protein solution). The solution containing purified *r*ARU was filtered sterilized by passage through a 22  $\mu$  filter and stored at 4°C. Purified *r*ARU along with samples from the steps of purification (lysate and dialyzed ammonium sulfate fraction) are shown in Fig. 5. The procedure typically yields approximately 100 mg *r*ARU per liter of *E. coli*/pRSETB-ARU-Km<sup>r</sup> culture. A combined 6-liter batch yielded 0.850 liters of *r*ARU at 0.88 mg/ml for a total of 748 mg of *r*ARU or 125 mg/liter of culture. The amount of *r*ARU recovered represented 23% of the total soluble protein.

### EXAMPLE 3

Construction of *r*BRU expression vector.

The vector pRSETC-BRU-Km<sup>r</sup> used for expression and purification was constructed using standard techniques for cloning (Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual* (1989)). The nucleotide sequence of the toxin B gene fragment encoding *r*BRU was derived from the cloned toxin B gene (Barroso *et al.*, *Nucleic Acids Res* 18:4004 (1990)) and is shown in Fig. 6. The gene fragment encodes a protein 622 amino acids in length with a molecular weight of approximately 70 kDa. The gene fragment was subcloned to the expression vector pRSETC. A kanamycin resistance gene was subsequently subcloned to the vector. The resulting vector pRSETC-BRU-Km<sup>r</sup> expresses *r*BRU.

### EXAMPLE 4

High-level expression and partial purification of *r*BRU.

One liter of *Escherichia coli* pRSETC-BRU-Km<sup>r</sup> was grown for 25 h at 37°C in a shaking incubator. Cells were harvested by centrifugation and resuspended in 0.1 liter phosphate buffered saline with 0.2% casamino acids. Supernatant of the culture at harvest had a pH of 6.2. Cells were disrupted by sonication and cellular debris was removed by centrifugation. The 10X lysate is shown in Fig. 9, lane 3.

### EXAMPLE 5.

Immune response to the *r*ARU component of the conjugates.

Antibodies to *C. difficile* toxin A (CDTA). Antibodies to native toxin A were measured by ELISA, with toxin A isolated from *C. difficile* as the coating antigen, and by in-vitro neutralization of cytotoxicity (Lyerly *et al. Infect. Immun.* 35:1147-1150 (1982)). Human intestinal epithelial HT-29 cells (ATCC HTB 38) were maintained in 96 well plates with McCoy's 5A medium supplemented with 10% fetal calf serum in a 5% CO<sub>2</sub> atmosphere. HT-29 cells were chosen because of their high sensitivity to CDTA probably because of the high density of the carbohydrate receptor on their surface. Serial 2-fold dilutions of sera were incubated with 0.4 µg/ml of CDTA for 30 min at room temperature. CDTA-serum mixtures were added to the wells at a final concentration of 20 ng of toxin A per well (about 200 times the minimal cytotoxic dose for HT-29 cells) in a final volume of 0.2 ml. The neutralization titer is expressed as the reciprocal of the highest dilution that

TABLE 1. Serum antibodies (µg/ml) to *Clostridium difficile* toxin A (CDTA) elicited in mice by recombinant enterotoxin A (*r*ARU) or polysaccharides bound to *r*ARU alone or succinylated (*r*ARUsucc)

Conjugate	µg <i>r</i> ARU injected	ELISA (Geometric mean and 25-75 centiles)		
		First injection	Second injection	Third injection
<i>r</i> ARU*	6.94	ND	ND	717 (621-863)
Pn14- <i>r</i> ARU	1.29	3.70 (2.55-5.08)	80.1 (69.8-131)	194 (113-236)
Pn14 <i>r</i> ARU succ	7.30	7.94 (5.21-11.3)	183 (146-175)	371 (274-463)
SF- <i>r</i> ARU	3.90	ND	433 (258-609)	613 (485-778)
SF- <i>r</i> ARUsucc	6.94	ND	191 (118-291)	518 (366-615)
SF- <i>r</i> ARU*	3.90	ND	ND	437 (372-547)
SF- <i>r</i> ARUsucc*	6.94	ND	ND	242 (172-443)
K1	8.08	10.7 (6.75-17.2)	84.9 (72.5-131)	390 (279-470)

183 vs 7.94 p=0.0001, 371 vs 183 p=0.0005, 80.1 vs 3.70 p=0.0001, 194 vs 80.1 p=0.007, 7.94 vs 3.70 p=0.01, 183 vs 80.1 p=0.004, 371 vs 194 p=0.01

\*hsd/ICR mice. Remainder were NIH SA mice. ND (not done).

6 wks-old mice were injected SC with 2.5 µg of polysaccharide as a conjugate at 2 wk intervals. Groups of mice (n=10) were exsanguinated 7 days after each injection and their sera assayed for anti-CDTA by ELISA. completely neutralized cytotoxicity.

All 5 conjugates elicited high levels of anti-CDTA (194-613 µg/ml) (Table 1). Since the 2.5 µg immunizing dose of the conjugates was based on its polysaccharide content, the amount of *r*ARU injected was different for each conjugate. For example, on a

protein weight basis. Pn14-*r*ARU, with 1.29  $\mu\text{g}$  of *r*ARU, elicited 194  $\mu\text{g}$  CDTA antibody/ml (150.3  $\mu\text{g}$  Ab/ $\mu\text{g}$  *r*ARU injected). In contrast, Pn14-*r*ARU*succ*, that contained 7.3  $\mu\text{g}$  of *r*ARU per dose, elicited 371  $\mu\text{g}$  CDTA antibody/ml (50.8  $\mu\text{g}$  Ab/ $\mu\text{g}$  *r*ARU*succ* injected). Pn14-*r*ARU induced more anti-CDTA per  $\mu\text{g}$  *r*ARU than Pn14-*r*ARU*succ*, however, the total amount of anti-CDTA elicited by Pn14-*r*ARU*succ* was greater due to its higher content of *r*ARU. The difference between the levels of anti-CDTA elicited by Pn14-*r*ARU (194  $\mu\text{g}$  CDTA antibody/ml) compared with Pn14-*r*ARU*succ* (371  $\mu\text{g}$  CDTA antibody/ml) was significant.

SF-*r*ARU, containing 3.9  $\mu\text{g}$  of *r*ARU, elicited 437  $\mu\text{g}$  CDTA antibody/ml (112.0  $\mu\text{g}$  Ab/ $\mu\text{g}$  *r*ARU injected) compared to 518  $\mu\text{g}$  CDTA antibody/ml for SF-*r*ARU*succ* (34.9  $\mu\text{g}$  Ab/ $\mu\text{g}$  *r*ARU*succ* injected). Although the specific immunogenic activity for the *r*ARU*succ* was lower than that of the *r*ARU in the SF conjugates, there was no statistical difference between the levels of CDTA antibody elicited by the two conjugates (437  $\mu\text{g}$  Ab/ml for SF-*r*ARU*succ* vs 242  $\mu\text{g}$  Ab/ml for SF-*r*ARU).

K1-*r*ARU*succ*, that elicited 390  $\mu\text{g}$  CDTA antibody/ml, had comparable specific immunogenic activity of its *r*ARU component (48  $\mu\text{g}$  Ab/ml per  $\mu\text{g}$  *r*ARU*succ*).

#### EXAMPLE 6

CDTA neutralizing antibodies.

Individual sera obtained 7 days after the third injection of the conjugates were assayed individually for their neutralization of approximately 200 times the cytotoxic dose of CDTA on human intestinal epithelial HT-29 cells. All sera from the mice immunized with the conjugates had a neutralizing titer greater than or equal to 64. The geometric mean and range of neutralizing titers for each conjugate is shown in Table 2.

TABLE 2. Serum neutralizing activity against the *in vitro* cytotoxicity for HT-29 cells of *Clostridium difficile* toxin A (CDTA)

Immunogen	$\mu\text{g Ab/ml}$ (ELISA)	Reciprocal neutralization titer (GM and range)	
Pn14- <i>r</i> ARU	194	104	64-256
Pn14- <i>r</i> ARU <i>succ</i>	371	111	64-128
SF- <i>r</i> ARU	613	194	64-256

Neutralizing titers were the highest serum dilution that completely inhibited the cytotoxicity of CDTA (20 ng/well) on HT-29 cells. The titers represent the geometric mean of sera from general purpose Swiss Albino mice (n=10) obtained 7 days after the 3rd injection. Anti-CDTA was measured by ELISA and the mean value expressed as  $\mu\text{g Ab/ml}$  serum.

\* Affinity purified goat antibody

#### EXAMPLE 7

Protection against lethal challenge with CDTA (Table 3).

Hsd/ICR mice were injected with SF-*r*ARU, SF-*r*ARU*succ* or *r*ARU as described in EXAMPLE 4 above. One week after the third injection, the mice were challenged intraperitoneally with a lethal dose (150 ng) of CDTA. Almost all mice vaccinated with either conjugate or *r*ARU were protected. Based upon the amount of *r*ARU injected, *r*ARU and SF-*r*ARU elicited similar levels of anti-CDTA. As expected, SF-*r*ARU*succ* elicited lower levels of anti-CDTA than the other two immunogens but the recipients were comparably protected.

Conjugate-induced antibody levels approached or surpassed the neutralizing activity of an affinity-purified goat antibody, containing 0.5 mg/ml, that was raised against formalin inactivated CDTA.

TABLE 3. Protection of mice against lethal challenge with 150 ng of *Clostridium difficile* toxin A (CDTA) <sup>a</sup> induced by vaccination with polysaccharide-*r*ARU conjugates

Immunogen	$\mu$ g <i>r</i> ARU injected	Survivals /total	CDTA antibodies (ELISA) <sup>b</sup>	Reciprocal neutralization titer <sup>c</sup>
<i>r</i> ARU	6.94	19/20	717 (621-863)	128-256
SF- <i>r</i> ARU	3.90	17/20	437 (372-547)	1 28-256
SF- <i>r</i> ARU <i>succ</i>	6.94	19/20	242 (172-443)	64-256
PBS	0	2/15	Not determined	<2

<sup>a</sup> Mice (hsd/ICR) injected I.P. with 150 ng of CDTA 7 days after the 3rd injection of *r*ARU or conjugate.

<sup>b</sup> Mean antibody level (25-75 centiles) of sera used for pool (n=10 from each group) bled 4 h before challenge with CDTA.

<sup>c</sup> Highest dilutions of sera (range) that completely neutralized the cytotoxicity of CDTA (20 ng/well) on HT-29 cells.

This invention has been described by a direct description and by examples. As noted above, the examples are meant to be only examples and not to limit the invention in any meaningful way. Additionally, one having ordinary skill in the art to which this invention pertains in reviewing the specification and claims which follow would appreciate that there are equivalents to those claimed aspects of the invention. The inventors intend to encompass those equivalents within the reasonable scope of the claimed invention.

## LITERATURE CITED

- U.S. Pat. No. 5,098,826 (Wilkins *et al.*) (1992).  
U.S. Pat. No. 5,736,139 (Kink *et al.*) (1998)  
U.S. Pat. No. 5,919,463 (Thomas *et al.*) (1999)  
Lyerly, D.M. and T.D. Wilkins. in *Infections of the Gastrointestinal Tract*, Chapter 58, pages 867-891. Raven Press, Ltd. New York 1995  
Moncrief *et al.*, *Infect. Immun.* 65:1105-1108 (1997);  
Barroso *et al.*, *Nucl. Acids Res.* 18:4004 (1990);  
Dove *et al.* *Infect. Immun.* 58:480-488 (1990)). (  
Krivan *et al.*, *Infect. Immun.* 53:573-581 (1986);  
Tucker, K. and T.D. Wilkins, *Infect. Immun.* 59:73-78 (1991)).  
Just *et al.* *Nature* 375:500-503 (1995),  
Just *et al.* *J. Biol. Chem* 270:13932-13939 (1995)).  
Hofmann *et al.* *J. Biol. Chem.* 272:11074-11078 (1997),  
Faust and Song, *Biochem. Biophys. Res. Commun.* 251:100-105 (1998))  
Lyerly *et al.* *Current Microbiology* 21:29-32 (1990)

## CLAIMS

1. An immunogenic composition comprising a recombinant protein component, wherein said protein component comprises at least one repeating unit of *C. difficile* toxin A (rARU) or at least one repeating unit of *C. difficile* toxin B (rBRU) or at least one repeating unit of each toxin A and toxin B.
2. The immunogenic composition of claim 1 wherein said recombinant protein component comprises at least two of said repeating units that are genetically fused to each other.
3. The immunogenic composition of claim 1 wherein said recombinant protein component comprises at least two of said repeating units that are chemically bound to each other.
4. The immunogenic composition of claim 1, wherein said composition elicits antibodies that neutralize toxin A or toxin B or both.
5. The immunogenic composition of claim 1 that elicits a protective response in a mammalian host against strains of *C. difficile*.
6. The immunogenic composition of claim 2 that elicits antibodies that neutralize toxin A or toxin B or both.
7. The immunogenic composition of claim 2 that elicits a protective response in a mammalian host against strains of *C. difficile*.
8. The immunogenic composition of claim 3 that elicits antibodies that neutralize toxin A or toxin B or both.
9. The immunogenic composition of claim 3 that elicits a protective response in a mammalian host against strains of *C. difficile*.

10. A pharmaceutical composition comprising the immunogenic composition of any one of claims 1-9 in a pharmaceutically acceptable carrier.

11. A method of conferring a protective response in a mammalian host comprising administering a therapeutically effective amount of the immunogenic composition of any one of claims 1-9 to a mammalian host.

12. A method of conferring a protective response in a mammalian host comprising administering a therapeutically effective amount of the pharmaceutical composition of claim 10 to a mammalian host.

13. The immunogenic composition of claim 1, wherein said protein component is toxin A or a fragment thereof.

14. The immunogenic composition of claim 13, wherein said protein component comprises a recombinant amino acid sequence that comprises the toxin A repeating units (rARU) or a fragment thereof.

15. The immunogenic composition of claim 14, wherein said protein is a fusion protein.

16. The immunogenic composition of claim 1, wherein said protein component is toxin B or a fragment thereof.

17. The immunogenic composition of claim 16, wherein said protein comprises a recombinant amino acid sequence that comprises the toxin B repeating units (rBRU) or a fragment thereof.

18. The immunogenic composition of claim 17, wherein said protein is a fusion protein.

19. The immunogenic composition of claim 1, wherein said immunogenic composition elicits in a mammalian host an immune response that is T-cell dependent.

20. The immunogenic composition of claim 1, wherein said immunogenic composition elicits in a mammalian host an immune response that is T-cell independent.

21. The immunogenic composition of claim 1, wherein said immunogenic composition elicits in a mammalian host an immune response that is both T-cell dependent and T-cell independent.

22. The immunogenic composition of claim 19 or 20 or 21, wherein said immune response is a cellular dependent immune response.

23. The immunogenic composition of claim 19 or 20 or 21, wherein said immune response results in a booster effect in said mammalian host.

24. The immunogenic composition of claim 19 or 20 or 21, wherein said immune response elicits a protective response to a strain of *C. difficile*.

25. The immunogenic composition of claim 19 or 20 or 21, wherein said immunogenic composition elicits a humoral immune response in a mammalian host.

26. The immunogenic composition of claim 19 or 20 or 21, wherein said immunogenic composition elicits both a humoral immune response and a cellular dependent immune response in a mammalian host.

27. The immunogenic composition of claim 19 or 20 or 21, wherein said immune response elicits a protective response to a strain of a *C. difficile*.

28. An immunogenic composition comprising a recombinant protein component, wherein said protein component comprises a recombinant amino acid sequence that comprises the *Clostridium difficile* toxin A repeating units (rARU) or a fragment thereof and wherein said composition further comprises a pharmaceutically acceptable carrier.

29. An immunogenic composition comprising a recombinant protein component, wherein said protein component comprises a recombinant amino acid sequence that comprises the *Clostridium difficile* toxin B repeating units (*rBRU*) or a fragment thereof and wherein said composition further comprises a pharmaceutically acceptable carrier.

30. An immunogenic composition comprising a recombinant protein component, wherein said protein component comprises a recombinant amino acid sequence that comprises the *Clostridium difficile* toxin A repeating units (*rARU*) or the *Clostridium difficile* toxin B repeating units (*rBRU*) or a fragment of either thereof and wherein said composition further comprises a pharmaceutically acceptable carrier.

31. An immunogenic composition comprising a recombinant protein component, wherein said protein component comprises a recombinant amino acid sequence that comprises the *Clostridium difficile* toxin A repeating units (*rARU*) or a fragment thereof and the *Clostridium difficile* toxin B repeating units (*rBRU*) or a fragment thereof and wherein said composition further comprises a pharmaceutically acceptable carrier.

32. A vaccine comprising the immunogenic composition of any one of claims 28, 29, 30 or 31.

33. The vaccine of claim 32, wherein said vaccine is formulated for use in humans.

34. The vaccine of claim 32, wherein said vaccine is formulated for use in animals.

35. A method for producing an immunogenic composition, comprising  
constructing a genetic sequence encoding a recombinant protein component,  
wherein said genetic sequence is isolated from a strain of *Clostridium difficile*;  
expressing said recombinant protein in a microbial host;  
recovering said recombinant protein from a culture of said host; and

recovering said recombinant protein component; and wherein said protein component is *Clostridium difficile* toxin A repeating unit (rARU) or fragment thereof or is *Clostridium difficile* toxin B repeating unit (rBRU) or fragment thereof.

36. The method of claim 35, wherein the expression of said genetic sequence is regulated by an inducible promoter operatively positioned upstream of said sequence and functional in said host.

37. The method of claim 36, wherein said microbial host is *Escherichia coli*.

38. The method of claim 37, wherein the recombinant protein is expressed at a level greater than about 10 mg/ml.

39. The method of claim 37, wherein the recombinant protein is expressed at a level greater than about 50 mg/liter of said culture.

40. The method of claim 37, wherein the recombinant protein is expressed at a level greater than about 100 mg/liter of said culture.

41. The method of claim 37, wherein said protein is greater than about 50kDa.

42. The method of claim 37, wherein said protein is greater than about 90kDa.

43. The method of claim 37, wherein said protein is recovered by ammonium sulfate precipitation followed by ion exchange chromatography.

44. The method of claim 37, wherein said protein is succinylated.

45. A recombinant genetic sequence comprising at least one gene encoding a protein component from a strain of *Clostridium difficile*.

46. The recombinant sequence of claim 45, wherein said gene encodes toxin A or a fragment thereof.

47. The recombinant sequence of claim 46, wherein said gene encodes the toxin A repeating units (*r*ARU) or a fragment thereof.

48. The recombinant sequence of claim 45, wherein said gene encodes toxin B or a fragment thereof.

49. The recombinant sequence of claim 48, wherein said gene encodes the toxin B repeating units (*r*BRU) or a fragment thereof.

50. The recombinant sequence of claim 45, comprising a first gene encoding toxin A or a fragment thereof and a second gene encoding toxin B or fragment thereof.

51. The recombinant sequence of claim 50, wherein said first gene encodes the toxin A repeating units (*r*ARU) or a fragment thereof and said second gene encodes the toxin B repeating units (*r*BRU) or a fragment thereof.

52. An expression vector comprising the genetic sequence of claim 45 or claim 50 and a gene that confers a selective phenotype upon a microbial host.

53. The expression vector of claim 52, wherein said selective phenotype is resistance to kanamycin.

54. A microbial host transformed with the expression vector of claim 52 or claim 53.

55. The use of the immunogenic composition of any one of claims 1-9 and 13-31 for the production of antibodies for passive immune therapy against a strain of said pathogenic microorganism.

1/11




Fig. 1

2/11

```

gatcctatag aattttaactt agtaactgga tggcaaaacta tcaatggtaa
aaaatattat tttgatataa atactggagc agctttaact agttataaaa
ttattaatgg taaacacttt tatttttaata atgatgggtg gatgcagtg
ggagtattta aaggacctga tggatttgaa tttttgcac ctgccaatac
tcaaaaataat aacatagaag gtcaggctat agtttatcaa agtaaatctt
taactttgaa tggcaaaaaa tattattttg ataataactc aaaagcagtc
actggatgga gaattattaa caatgagaaa tattacttta atcctaataa
tgctattgct gcagtcggat tgcaagtaat tgacaataat aagtattatt
tcaatcctga cactgctatc atctcaaaaag gttggcagac tgtaaatggt
agtagatact actttgatac tgataccgct attgccttta atggttataa
aactattgat ggtaaacact tttattttga tagtgattgt gtagtgaaaa
taggtgtggt tagtacctct aatggatttg aatattttgc acctgctaata
acttataata ataacataga aggtcaggct atagtttatc aaagtaaat
cttaactttg aatggtaaaa aatattactt tgataataac tcaaaagcag
ttaccggatg gcaaacctatt gatagtaaaa aatattactt taatactaac
actgctgaag cagctactgg atggcaaaact attgatggta aaaaatatta
ctttaatact aacactgctg aagcagctac tggatggcaa actattgatg
gtaaaaaata ttacttttaa actaacactg ctatagcttc aactggttat
acaattatta atggtaaaaca tttttatttt aatactgatg gtattatgca
gataggagtg tttaaaggac ctaatggatt tgaatathtt gcacctgcta
atacggatgc taacaacata gaaggtcaag ctatacttta ccaaaatgaa
ttcttaactt tgaatggtaa aaaatattac tttggtagtg actcaaaagc
agttactgga tggagaatta ttaacaataa gaaatattac ttaatccta
ataatgctat tgctgcaatt catctatgca ctataaataa tgacaagtat
tactttagtt atgatggaat tcttcaaaaat ggatatatta ctattgaaag
aaataatttc tattttgatg ctaataatga atctaaaatg gtaacaggag
tatttaaagg acctaatgga tttgagtatt ttgcacctgc taatactcac
aataataaca tagaaggcca aaaaaatatt ggcataagtt taccagaaca
gttgcaaac cattgatggt aaaaaatatt aactattgat aattcctaac
gaagcagcta ctggatggca aactattgat ggtaaaaaat gcagttactg
tcttaacact gctgaagcag actttcatag gtaaaaaaat taacactgct
aatattactt taatactaac aacattttta attttgataa attactttaa
attaatggta ggacctaatg gatttgaata ctttgcacct gctattttaa
agtgtttaaa ggacctaatg caagctatac tttaccaaaa gatggtaaaa
atgctaacaa catagaaggt ttactttggt agtgactcaa aagcagttac
actttgaaat gtaaaaaata ttaactttaat actaacactg
cggactgcca actattgatg gtaaaaaata atggtaaaaa atactacttt
ctgttgcagt tactggatgg caaactatta atggtataaa ttagtggtaa
aatactaaca cttctatagc ttcaactggt tacaactggt gcagatagga
acatttttat tttaatactg atgggtattat gcaatacaga tgctaacaat
gacctgatgg atttgaatac tttgcaacct ctaatacaga atttacatga
atagaaggtc aagctatacg ttatcaaaaat agattcctat ggttgggtaa
caatataat tattttggta ataattcaaa agcggctact ggttgggtcg
ctattgatgg taatagatat tacttcgagc ctaatacagc tatgggtgcg
aatggttata aaactattga taataaaaaat ttttacttta gaaatggttt
acctcagata ggagtgttta aaggtctaa tggatttgaa tactttgcac
ctgctaatac ggatgctaac aatatagaag gtcaagctat acgttatcaa
aatagattcc tacatttact tggaaaaata tattactttg gtaataatcc
aaaagcagtt actggatggc aaactattaa tggtaaaagta tattacttta
tgccctga

```

Fig. 2

3/11

DPIEFNLVTGWQTINGKKYYFDINTGAALTSYKIINGKHFY  
FNNDGVMQLGVFKGPDGFYFAPANTQNNNIEGQAIIVYQSK  
FLTLNGKKYYFDNNSKAVTGWRIINNEKYYFNPNNIAAVG  
LQVIDNNKYYFNPDTAIIISKGWQTVNGSRYYFDTDTAIAFN  
GYKTIDGKHFYFSDCVVKIGVFSTSNGFYFAPANTYNNN  
IEGQAIIVYQSKFLTLNGKKYYFDNNSKAVTGWQTIIDSKKYY  
FNTNTAEAAATGWQTIIDGKKYYFNTNTAEAAATGWQTIIDGKKY  
YFNTNTAIASTGYTIINGKHFYFNTDGIMQIGVFKGPNNGFE  
YFAPANTDANNIEGQAILYQNEFLTLNGKKYYFGSDSKAVT  
GWRIINNKKYYFNPNNIAAAIHLCTINNDKYYFSYDGI LQN  
GYITIERNNFYFDANNESKMVTGVFKGPNNGFEYFAPANTHN  
NNIEGQAIIVYQNKFLTLNGKKYYFDNNSKAVTGWQTIIDGKK  
YYFNLNTAEAAATGWQTIIDGKKYYFNLNTAEAAATGWQTIIDGK  
KYYFNTNTFIASSTGYTSINGKHFYFNTDGIMQIGVFKGPNNG  
FEYFAPANTDANNIEGQAILYQNKFLTLNGKKYYFGSDSKA  
VTGLRTIDGKKYYFNTNTAVAVTGWQTINGKKYYFNTNTSI  
ASTGYTIIISGKHFYFNTDGIMQIGVFKGPDGFYFAPANTD  
ANNIEGQAIRYQNRFLYLHDNIYYFGNNSKAATGWVTIDGN  
RYFEPNTAMGANGYKTIDNKNFYFRNGLPQIGVFKGSNGF  
EYFAPANTDANNIEGQAIRYQNRFLHLLGKIYYFGNNSKAVT  
GGWQTINGKVYYFMPDTAMAAAGGLFEDGVIYFFGVVDGVKA  
PGIYG\*

Fig. 3




Fig. 4

5/11




Fig. 5

6/11

```

gatctatcta tacgatatgt atggagtaat gatggtaatg attttattct tatgtcaact
agtgaagaaa ataaggtgtc acaagttaa ataagattcg ttaatgttt taaagataag
actttggcaa ataagctatc ttttaacttt agtgataaac aagatgtacc tgaagtga
ataatcttat catttacacc ttcatattat gaggatggat tgattggcta tgattgggt
ctagtttctt tatataatga gaaattttat attaataact ttggaatgat ggtatctgga
ttaatatata ttaatgattc attatattat tttaaaccac cagtaaataa tttgataact
ggatttgtga ctgtaggcga tgataaatac tactttaatc caattaatgg tggagctgct
tcaattggag agacaataat tgatgacaaa aattattatt tcaaccaaag tggagtgtta
caaacaggtg tatttagtac agaagatgga tttaaatatt ttgccccagc taatacactt
gatgaaaacc tagaaggaga agcaattgat tttactggaa aattaattat tgacgaaaat
athtattatt ttgatgataa ttatagagga gctgtagaat ggaaagaatt agatggtgaa
atgcactatt ttagcccaga aacaggtaaa gcttttaaag gtctaaatca aataggtgat
tataaatact atttcaattc tgatggagtt atgcaaaaag gatttgttag tataaatgat
aataaacact attttgatga ttctgggtgtt atgaaaatag gttacactga aatagatggc
aagcatttct actttgctga aaacggagaa atgcaaatag gagtatttaa tacagaagat
ggatttaa attttgctca tcataatgaa gatttaggaa atgaagaagg tgaagaaatc
tcatattctg gtatattaaa tttcaataat aaaatttact attttgatga ttcatttaca
gctgtagtgg gatggaaaga ttttagaggat ggttcaaagt attattttga tgaagataca
gcagaagcat atataggttt gtcattaata aatgatggtc aatattattt taatgatgat
ggaattatgc aagttggatt tgtcactata aatgataaag tcttctactt ctctgactct
ggaattatag aatctggagt acaaaacata gatgacaatt atttctatat agatgataat
ggtatagttc aaattgggtgt atttgatact tcagatggat ataaatattt tgcacctgct
aatactgtaa atgataatat ttacggacaa gcagttgaa atagtggttt agtttagagtt
ggggaagatg tatattattt tggagaaaca tatacaattg agactggatg gatatatgat
atggaaaatg aaagtgataa atattatttc aatccagaaa ctaaaaaagc atgcaaaggt
attaatttaa ttgatgatat aaaatattat tttgatgaga agggcataat gagaacgggt
cttatatcat ttgaaaataa taattattac tttaatgaga atggtgaaat gcaatttgggt
tatataaata tagaagataa gatgttctat tttgggtgaag atgggtgcat gcagattgga
gtatttaata caccagatgg atttaaatac tttgcacatc aaaatacttt ggatgagaat
tttgagggag aatcaataaa ctatactggt tggttagatt tagatgaaaa gagatattat
tttacagatg aatatattgc agcaactggt tcagttatta ttgatgggtg ggagtattat
tttgatcctg atacagctca attagtgatt agtgaataga taaaaatag ttaaataat
cctcttatac ttaaataat aaaaataaac aaaatgatac actacataaa gtgttctatc
taatatgaag atttaccaat aaaaaggtgg actatgatga atgcacagta gttcaccttt
ttatattact aatggtaaca aatathtttt ttatataaac ctaggaggcg tt//

```

Fig. 6

7/11

DLSIRYVWSNDGNDFILMSTSEENKVSQVKIRFVNVFKDKTLANKLSFNF  
SDKQDVPVSEIILSFTPSYYEDGLIGYDLGLVSLYNEKFYINNFGMMVSG  
LIYINDSLYYFKPPVNNLITGFVTVGDDKYYFNPINGGAASIGETIIDDK  
NYYFNQSGVLQTVGFSTEDGFKYFAPANTLDENLEGEAIDFTGKLIIDEN  
IYFDDNYRGAVEWKELDGEMHYFSPETGKAFKGLNQIGDYKYYFNSDGVM  
QKGFVSINDNKHYFDDSGVMKVGYTEIDGKHFYFAENGEMQIGVFNTEDG  
FKYFAHNEDLGNEEGEEISYSGILNFNNKIYYFDDSF TAVVGWKDLEDG  
SKYYFDEDTAEAYIGLSLINDGQYYFNDDGIMQVGFVTINDKVYFSDSG  
IIESGVQNIDDNYFYIDDNGIVQIGVFDTSDGYKYFAPANTVNDNIYGQA  
VEYSGLVRVGEDVYYFGETYTIETGWIYDMENESDKYYFNPETKKACKGI  
NLIDDIKYYFDEKGI MRTGLISFENNNYYFNENGEMQFGYINIEDKMFYF  
GEDGVMQIGVFNTPDGFKYFAHQNTLDENFEGESINYTGWLDLDEKRYF  
TDEYIAATGSVIIDGEEYYFDPDTAQLVISE

Fig. 7




Fig. 8




Figure 9

10/11




Figure 10




Fig. 11

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/09525

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 C12N15/31 C12N15/62 C12N1/21 C07K14/33 A61K38/16

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**  
 Minimum documentation searched (classification system followed by classification symbols)  
 IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)  
 EPO-Internal, WPI Data, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 12802 A (KINK JOHN A ;FIRCA JOSEPH R (US); PADHYE NISHA V (US); THALLEY BRU) 2 May 1996 (1996-05-02) abstract examples 1,2,7-11,15,18-21,28-53 -----	1-55
A	WO 97 02836 A (ORAVAX INC) 30 January 1997 (1997-01-30) abstract examples 1-5 -----	1-55

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

<p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>
--	--

Date of the actual completion of the international search	Date of mailing of the international search report
14 September 2000	20/09/2000

Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer  <p style="text-align: center;">Galli, I</p>
--	---

## INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 00/09525

Patent document cited in search report	Publication date	Patent family member(s)	Publication date		
WO 9612802 A	02-05-1996	US 5736139 A	07-04-1998		
		US 5919665 A	06-07-1999		
		US 5601823 A	11-02-1997		
		US 5196193 A	23-03-1993		
		AU 709586 B	02-09-1999		
		AU 3968395 A	15-05-1996		
		AU 4876399 A	25-11-1999		
		BR 9509903 A	25-11-1997		
		CA 2203504 A	02-05-1996		
		CN 1176658 A	18-03-1998		
		CZ 9701250 A	18-03-1998		
		EP 0796326 A	24-09-1997		
		FI 971732 A	23-06-1997		
		HU 78048 A	28-07-1999		
		NO 971868 A	24-06-1997		
		NZ 295998 A	28-10-1999		
		PL 320214 A	15-09-1997		
		ZA 9508990 A	15-05-1996		
		AU 688763 B	19-03-1998		
		AU 6653894 A	04-07-1994		
		CA 2150935 A	23-06-1994		
		EP 0671902 A	20-09-1995		
		WO 9413264 A	23-06-1994		
		US 5762934 A	09-06-1998		
		US 5814477 A	29-09-1998		
		US 5466672 A	14-11-1995		
		US 5599539 A	04-02-1997		
		US 5719267 A	17-02-1998		
		AT 170079 T	15-09-1998		
		AU 638786 B	08-07-1993		
		AU 6895191 A	31-05-1991		
		DE 69032599 D	01-10-1998		
		EP 0498854 A	19-08-1992		
		WO 9106306 A	16-05-1991		
		US 5443976 A	22-08-1995		
		US 5904922 A	18-05-1999		
		US 5340923 A	23-08-1994		
		WO 9702836 A	30-01-1997	US 5919463 A	06-07-1999
				AU 720567 B	08-06-2000
				AU 6404796 A	10-02-1997
				CA 2226339 A	30-01-1997
				CN 1195297 A	07-10-1998
				EP 0837692 A	29-04-1998
JP 11509200 T	17-08-1999				
NZ 312502 A	29-03-1999				

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 13-15,28,46,47 and partly 1-12,19-27,30-45,50-55

An immunogenic composition comprising a recombinant protein component, wherein said component comprises at least one repeating unit of *C. difficile* toxin A (rARU). Formulations, vaccines and uses thereof.

A recombinant genetic sequence comprising at least one gene encoding a protein component from a strain of *C. difficile*, wherein said gene encodes toxin A or a fragment thereof, in particular the repeating unit (ARU). Corresponding vectors, recombinant host cells.

2. Claims: 16-18,29,48,49 and partly 1-12,19-27,30-45,50-55

Idem as subject matter 1, but limited to *C. difficile* toxin B and its repeating units (BRU).